intervention only increased the pupillary diameter to 3.5 mm.
The iris was noted to be atonic and had a propensity to prolapse out of the main clear corneal incision. A diagnosis of intraoperative floppy iris syndrome was suspected. Routine cataract surgery could not proceed with such a small pupil size. Four iris retracting hooks were needed to stretch the pupil to over 6 mm to enable the cataract to be removed ( Fig. 1) .
Postoperatively, the patient's best-corrected visual acuity in his left eye improved to 6/12 on day one and 6/6 at four weeks.
Comment
Intraoperative floppy iris syndrome is a condition characterised by: The most important factor governing cataract surgery outcomes in patients on an alpha 1 adrenergic antagonist is recognition of its ability to induce intraoperative floppy iris syndrome. The astute surgeon can then plan a suitable management approach. Some studies have shown floppy iris syndrome as high as 12%, 2 falling to 0.6% when the surgeon is aware the patient has used tamsulosin. 1
Conclusion
As cataracts and the use of alpha 1 adrenergic antagonists increase with age, it is not surprising that the incidence of intraoperative floppy iris syndrome has been reported to occur in up to 3.7% of cataract surgeries. 2 
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Drug information resources
As of 1 July 2010 the Therapeutic Advice and Information Service (TAIS) national drug information service for health professionals will no longer be operational. The National
Prescribing Service acknowledges the dedication and expertise of the staff who contributed to the high quality of TAIS over its ten years of operation.
Closer to the cessation date, health professionals will be able to access an index of other sources of drug information on the NPS website at www.nps.org.au/ health_professionals. Please note that while some of these Azacitidine is an analogue of cytidine, one of the nucleosides which make up nucleic acids. When azacitidine is incorporated into DNA it inhibits DNA methyltransferase, reducing hypermethylation, and has a direct cytotoxic effect on abnormally proliferating cells.
In the first treatment cycle azacitidine is given by daily subcutaneous injection for seven days. This cycle is repeated every four weeks for as long as the patient continues to benefit.
Most of the dose is excreted in the urine as azacitidine and its metabolites. Azacitidine is contraindicated in patients with malignant hepatic tumours and those with renal failure.
After phase II trials of intravenous and subcutaneous doses produced favourable results, a phase III trial was carried out in 191 patients with myelodysplasia. These patients were randomly assigned to azacitidine or supportive care. They were assessed after four treatment cycles, and those who had responded to azacitidine could continue. Responses were assessed by changes in the blood and bone marrow and the need for transfusion. In the azacitidine group, 16% of the patients had a partial response and 7% had a complete response. The median duration of all the improvements was 15 months.
No-one in the supportive care group had a complete or a partial Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may be limited published data and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source.
New drugs
